Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations?

The Korean Journal of Internal Medicine
W W Yew, Won-Jung Koh

Abstract

A worsening scenario of drug-resistant tuberculosis has increased the need for new treatment strategies to tackle this worldwide emergency. There is a pressing need to simplify and shorten the current 6-month treatment regimen for drug-susceptible tuberculosis. Rifamycins and fluoroquinolones, as well as several new drugs, are potential candidates under evaluation. At the same time, treatment outcomes of patients with drug-resistant tuberculosis should be improved through optimizing the use of fluoroquinolones, repurposed agents and newly developed drugs. In this context, the safety and tolerance of new therapeutic approaches must be addressed.

References

Dec 18, 1976·Lancet·W Fox, D A Mitchison
Mar 13, 2002·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·W W Yew
Jan 10, 2003·American Journal of Respiratory and Critical Care Medicine·Amina JindaniDenis A Mitchison
Oct 28, 2003·American Journal of Respiratory and Critical Care Medicine·Eric L NuermbergerJacques H Grosset
Aug 13, 2004·American Journal of Respiratory and Critical Care Medicine·Eric L NuermbergerJacques H Grosset
Feb 15, 2005·American Journal of Respiratory and Critical Care Medicine·Denis A Mitchison
Apr 5, 2005·American Journal of Respiratory and Critical Care Medicine·Frik A SirgelDenis A Mitchison
Jan 25, 2006·British Journal of Pharmacology·Lee JiaJoseph E Tomaszewski
May 6, 2006·American Journal of Respiratory and Critical Care Medicine·William J BurmanRichard E Chaisson
Sep 21, 2007·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·H M J NijlandR E Aarnoutse
Jan 14, 2009·Antimicrobial Agents and Chemotherapy·Jean C SungDavid A Edwards
May 2, 2009·American Journal of Respiratory and Critical Care Medicine·Susan E DormanUNKNOWN Tuberculosis Trials Consortium
Jun 6, 2009·The New England Journal of Medicine·Andreas H DiaconDavid F Mc Neeley
Oct 31, 2009·American Journal of Respiratory and Critical Care Medicine·Galina V MukamolovaMichael R Barer
Apr 14, 2010·Antimicrobial Agents and Chemotherapy·Venkata M ReddyCarol A Nacy
May 6, 2010·American Journal of Respiratory and Critical Care Medicine·Armand Van DeunHans L Rieder
May 26, 2010·Antimicrobial Agents and Chemotherapy·Andreas H DiaconMelvin K Spigelman
Jun 1, 2010·The Lancet Infectious Diseases·David J HorneKaren R Steingart
Sep 28, 2010·Expert Opinion on Emerging Drugs·Wing Wai YewYing Zhang
Jun 21, 2011·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·A H DiaconP R Donald
Aug 11, 2011·The European Respiratory Journal·D FalzonM Zignol
Dec 23, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Zarir F UdwadiaCamilla Rodrigues
Feb 14, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·M C PayenN Clumeck
Feb 14, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·H Cox, N Ford
Mar 7, 2012·Antimicrobial Agents and Chemotherapy·Ying ZhangMichael R Barer
Mar 21, 2012·Antimicrobial Agents and Chemotherapy·Andreas H DiaconMelvin K Spigelman
Apr 13, 2012·The European Respiratory Journal·Giovanni SotgiuGiovanni Battista Migliori
May 23, 2012·The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·D Mitchison, G Davies
Jun 8, 2012·The New England Journal of Medicine·Maria Tarcela GlerCharles D Wells
Jul 19, 2012·The Journal of Infectious Diseases·Kelly E DooleyUNKNOWN Efficacy Subgroup, RESIST-TB
Jul 26, 2012·AIDS Research and Treatment·Kelly E DooleyRichard Hafner
Aug 2, 2012·The Journal of Infectious Diseases·Susan E DormanUNKNOWN Tuberculosis Trials Consortium
Sep 5, 2012·Respirology : Official Journal of the Asian Pacific Society of Respirology·Kwok-Chiu Chang, Wing-Wai Yew
Sep 22, 2012·The European Respiratory Journal·Saverio De LorenzoGiovanni Battista Migliori
Sep 29, 2012·The European Respiratory Journal·Vija SkripconokaCharles D Wells
Oct 12, 2012·The Journal of Antimicrobial Chemotherapy·Teesta DeyNathan Ford
Oct 19, 2012·The New England Journal of Medicine·Myungsun LeeClifton E Barry
Nov 13, 2012·International Journal of Pharmaceutics·Ju-Hwan ParkChang-Koo Shim
Nov 28, 2012·Antimicrobial Agents and Chemotherapy·Rahul Kumar VermaAmit Misra

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT00814671
NCT00728507
NCT01516203
NCT01918397
NCT01424670

Software Mentioned

Opti
STREAM

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Related Papers

Vojnosanitetski pregled. Military-medical and pharmaceutical review
V DangubićV Bulatović
Bulletin of the International Union Against Tuberculosis
N A Schmelev
Journal of the Tennessee Medical Association
C E Kossmann
The European Respiratory Journal
J P Zellweger
© 2022 Meta ULC. All rights reserved